Company
Becton, Dickinson and Company
Headquarters: Franklin Lakes, NJ, United States
Founded: East Rutherford, New Jersey 1897
Employees: 75,000
CEO: Mr. Thomas E. Polen Jr.
Market Cap
$70.33 Billion
USD as of Jan. 1, 2024
Becton, Dickinson and Company Categories
United States Healthcare Medical Instruments & SuppliesUnited States Healthcare United States Medical Instruments & Supplies
Company Description
Becton, Dickinson and Company, more simply known as BD, is a medical technology company. It manufactures and markets medical devices, instrument systems, reagents, and provides consulting and analytics services. Founded in 1897, BD was a pioneer of syringes that expanded to other medical supplies such as needles, catheters, and developed a range of medical, diagnostic and research devices.
Top Competitors by Market Capitalization
Industry: Medical Instruments & Supplies
| Company | Market Cap (USD) |
|---|---|
| Intuitive Surgical, Inc. | $113.81 B |
| EssilorLuxottica SA | $90.57 B |
| HOYA Corp | $43.39 B |
| Alcon Inc. | $37.65 B |
| West Pharmaceutical Services, Inc. | $25.08 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Becton, Dickinson and Company has the following listings and related stock indices.
Stock: NYSE: BDX wb_incandescent
Stock: BMV: BDX wb_incandescent
Stock: Bovespa: B1DX34 wb_incandescent
Stock: NYSE: BDXB wb_incandescent
Stock: XETR: BOX wb_incandescent
Key People
Founder(s): Maxwell Becton and Fairleigh S. Dickinson
Tom Polen (Chairman, CEO and President) Christopher R. Reidy (Executive Vice President and CAO) Christopher Del Orefice (Executive Vice President and CFO)
Financials
Revenue: US$20.248 Billion (Fiscal Year Ended September 30, 2021)
Operating income: US$2.799 Billion (Fiscal Year Ended September 30, 2021)
Net income: US$2.002 Billion (Fiscal Year Ended September 30, 2021)
Total assets: US$53.866 Billion (Fiscal Year Ended September 30, 2021)
Total equity: US$23.677 Billion (Fiscal Year Ended September 30, 2021)